LB PHARMACEUTICALS INC
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Non-accelerated filerSmaller reporting companyEmerging growth company
State of Incorporation
DE
Business Address
575 MADISON AVENUE, NEW YORK, NY, 10022
Mailing Address
575 MADISON AVENUE, NEW YORK, NY, 10022
Phone
917-450-6581
Fiscal Year End
1231
EIN
000000000
Financial Overview
FY2025
$312.93M
Total Assets
$250.17M
Cash & Equivalents
$-3.13
EPS
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| S-1 IPO registration statement | April 6, 2026 | View on SEC |
| 8-K Current report of material events | March 26, 2026 | View on SEC |
| 10-K Annual financial report | March 26, 2026 | View on SEC |
| 8-K Current report of material events | March 16, 2026 | View on SEC |
| 3 Initial insider ownership report | March 10, 2026 | View on SEC |
| 4 Insider stock transaction report | March 10, 2026 | View on SEC |
| 8-K Current report of material events | March 10, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | February 17, 2026 | View on SEC |
| 4 Insider stock transaction report | February 10, 2026 | View on SEC |
| SCHEDULE 13D/A Beneficial ownership amendment | February 10, 2026 | View on SEC |
Annual Reports
10-K
March 26, 2026
- Lead drug candidate LB-102 is entering critical Phase 3 testing for schizophrenia.
- Successful IPO in September 2025 raised $150 million to fund operations through 2027.
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.